Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palovarotene Extension Study in FOP
NCT02279095Phase 2Completed
- Sponsor
- Clementia Pharmaceuticals Inc.
- Start
- Oct 2014
- Primary completion
- Sep 2022
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
A Phase 2 trial of palovarotene in fibrodysplasia ossificans progressiva (FOP), sponsored by Clementia Pharmaceuticals Inc.. Started Oct 2014; status: completed.
02
Drugs
palovarotene
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NCT02279095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02279095.